[go: up one dir, main page]

MA32731B1 - Céphalosporine possédant un groupe catéchol - Google Patents

Céphalosporine possédant un groupe catéchol

Info

Publication number
MA32731B1
MA32731B1 MA33798A MA33798A MA32731B1 MA 32731 B1 MA32731 B1 MA 32731B1 MA 33798 A MA33798 A MA 33798A MA 33798 A MA33798 A MA 33798A MA 32731 B1 MA32731 B1 MA 32731B1
Authority
MA
Morocco
Prior art keywords
similar
cepham compound
protected
ester
substituted
Prior art date
Application number
MA33798A
Other languages
Arabic (ar)
English (en)
Inventor
Yasuhiro Nishitani
Kenji Yamawaki
Yusuke Takeoka
Hideki Sugimoto
Shinya Hisakawa
Toshiaki Aoki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42128829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32731(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MA32731B1 publication Critical patent/MA32731B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ DE CÉPHÈME REPRÉSENTÉ PAR LA FORMULE (I) [DANS LAQUELLE X REPRÉSENTE N, CH OU C-CL ; T REPRÉSENTE S OU SIMILAIRE ; A ET G REPRÉSENTENT INDÉPENDAMMENT UN ALKYLÈNE INFÉRIEUR OU SIMILAIRE ; B REPRÉSENTE UNE SIMPLE LIAISON OU SIMILAIRE ; D REPRÉSENTE UNE SIMPLE LIAISON, -NR7-CO-, -CO-NR7-, 'NR7-CO-NR7- OU SIMILAIRE ; E REPRÉSENTE UN ALKYLÈNE INFÉRIEUR QUI PEUT ÊTRE SUBSTITUÉ ; F REPRÉSENTE UNE SIMPLE LIAISON OU UN PHÉNYLÈNE QUI PEUT ÊTRE SUBSTITUÉ ; R3, R4, R5 ET R6 REPRÉSENTENT CHACUN INDÉPENDAMMENT UN HYDROGÈNE, UN HALOGÈNE, UN NITRILE OU 'OR8 ; R8 REPRÉSENTE UN HYDROGÈNE OU SIMILAIRE ; ET UN GROUPE REPRÉSENTÉ PAR LA FORMULE (II) REPRÉSENTE UN GROUPE AMMONIUM QUATERNAIRE MONOCYCLIQUE OU À CYCLES CONDENSÉS SATURÉ OU INSATURÉ QUI POSSÈDE AU MOINS UN ATOME N ET QUI PEUT ÊTRE SUBSTITUÉ, LA LIGNE TIRETÉE REPRÉSENTANT UNE LIAISON DANS LE CYCLE], UN ESTER DU COMPOSÉ DE CÉPHÈME, UN PRODUIT PROTÉGÉ DU COMPOSÉ DE CÉPHÈME DANS LEQUEL UN GROUPE AMINO, SITUÉ SUR LE NOYAU DANS LA CHAÎNE DU CÔTÉ DE LA POSITION 7, EST PROTÉGÉ, UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DU COMPOSÉ DE CÉPHÈME, DE L'ESTER OU DU PRODUIT PROTÉGÉ, OU UN SOLVATE DU COMPOSÉ DE CÉPHÈME, DE L'ESTER, DU PRODUIT PROTÉGÉ OU DU SEL PHARMACEUTIQUEMENT ACCEPTABLE, QUI PRÉSENTE UN LARGE SPECTRE ANTIBACTÉRIEN ET EN PARTICULIER QUI PRÉSENTE UNE ACTIVITÉ ANTIBACTÉRIENNE PUISSANTE VIS-À-VIS DE BACTÉRIES À GRAM NÉGATIF PRODUISANT DE LA ß-LACTAMASE. L'INVENTION PORTE ÉGALEMENT SUR UNE COMPOSITION PHARMACEUTIQUE RENFERMANT LE COMPOSÉ DE CÉPHÈME, L'ESTER, LE PRODUIT PROTÉGÉ, LE SEL PHARMACEUTIQUEMENT ACCEPTABLE OU LE SOLVATE.
MA33798A 2008-10-31 2011-04-29 Céphalosporine possédant un groupe catéchol MA32731B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008280828 2008-10-31
PCT/JP2009/068400 WO2010050468A1 (fr) 2008-10-31 2009-10-27 Céphalosporine possédant un groupe catéchol

Publications (1)

Publication Number Publication Date
MA32731B1 true MA32731B1 (fr) 2011-10-02

Family

ID=42128829

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33798A MA32731B1 (fr) 2008-10-31 2011-04-29 Céphalosporine possédant un groupe catéchol

Country Status (38)

Country Link
US (1) US9238657B2 (fr)
EP (2) EP2341053B1 (fr)
JP (2) JP5498393B2 (fr)
KR (1) KR101655961B1 (fr)
CN (1) CN102203100B (fr)
AU (1) AU2009310959B2 (fr)
BR (1) BRPI0921701B8 (fr)
CA (1) CA2736953C (fr)
CL (1) CL2011000939A1 (fr)
CO (1) CO6331443A2 (fr)
CR (1) CR20110144A (fr)
CY (2) CY1118536T1 (fr)
DK (1) DK2960244T3 (fr)
EA (1) EA019520B1 (fr)
ES (2) ES2564836T3 (fr)
FI (1) FIC20200039I1 (fr)
FR (1) FR20C1050I2 (fr)
HR (1) HRP20161408T1 (fr)
HU (2) HUE031802T2 (fr)
IL (1) IL211720A (fr)
LT (2) LT2960244T (fr)
MA (1) MA32731B1 (fr)
ME (1) ME02666B (fr)
MX (1) MX2011004636A (fr)
MY (1) MY155655A (fr)
NL (1) NL301067I2 (fr)
NO (1) NO2020035I1 (fr)
NZ (1) NZ591728A (fr)
PE (1) PE20120010A1 (fr)
PL (1) PL2960244T3 (fr)
PT (1) PT2960244T (fr)
RS (1) RS55365B1 (fr)
SI (1) SI2960244T1 (fr)
SM (1) SMT201600397B (fr)
TW (1) TWI535727B (fr)
UA (1) UA105190C2 (fr)
WO (1) WO2010050468A1 (fr)
ZA (1) ZA201102024B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883772B2 (en) 2007-10-09 2014-11-11 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
BRPI0921701B8 (pt) * 2008-10-31 2022-11-29 Shionogi & Co Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende
US8883773B2 (en) 2010-04-05 2014-11-11 Shionogi & Co., Ltd. Cephem compound having pseudo-catechol group
AU2011236933A1 (en) * 2010-04-05 2013-05-02 Shionogi & Co., Ltd. Cephem compound having catechol group
JP5852562B2 (ja) * 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体
EP2966061B1 (fr) 2011-03-04 2017-05-03 Life Technologies Corporation Composés et procédés de conjugaison de biomolécules
KR101719556B1 (ko) * 2011-03-30 2017-03-24 주식회사 레고켐 바이오사이언스 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
CA2833121A1 (fr) 2011-04-28 2012-11-01 Shionogi & Co., Ltd. Nouveau compose de cepheme ayant la structure du catechol ou une structure proche du catechol
US9242999B2 (en) 2011-06-27 2016-01-26 Shionogi & Co., Ltd. Cephem compound having pyridinium group
TWI547496B (zh) * 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
WO2013051597A1 (fr) 2011-10-04 2013-04-11 塩野義製薬株式会社 Dérivé céphem ayant un groupe catéchol
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
CN104854113A (zh) 2012-10-29 2015-08-19 盐野义制药株式会社 2-烷基头孢烯化合物的中间体的生产方法
WO2014104148A1 (fr) * 2012-12-26 2014-07-03 塩野義製薬株式会社 Composé de céphem
ES2800603T3 (es) 2013-09-09 2021-01-04 Merck Sharp & Dohme Tratamiento de infecciones con ceftolozano/tazobactam en sujetos con insuficiencia renal
WO2015148379A1 (fr) 2014-03-24 2015-10-01 Novartis Ag Composés organiques monobactam pour le traitement d'infections bactériennes
JP6377570B2 (ja) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−置換セフェム化合物を含有する医薬組成物
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
PT3190115T (pt) 2014-09-04 2021-10-19 Shionogi & Co Sal de derivado de cefalosporina, forma sólida cristalina do mesmo e método para produzir o mesmo
CN106661052B (zh) * 2014-09-04 2021-05-11 盐野义制药株式会社 头孢菌素衍生物的中间体及其制造方法
US9949982B2 (en) 2014-09-04 2018-04-24 Shionogi & Co., Ltd. Preparation containing cephalosporin having a catechol moiety
JP2018521021A (ja) 2015-06-11 2018-08-02 バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ 排出ポンプ阻害剤及びその治療的使用
EA202092620A1 (ru) 2015-09-23 2021-06-30 Новартис Аг Соли и твердые формы монобактамного антибиотика
US9751894B2 (en) * 2015-12-10 2017-09-05 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
EP3471724A1 (fr) * 2016-06-17 2019-04-24 Wockhardt Limited Compositions anti-bactériennes
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3634471A4 (fr) * 2017-06-09 2021-02-24 FOB Synthesis, Inc. Composés de carbapenem et compositions pour le traitement d'infections bactériennes
AU2018311521B2 (en) 2017-08-02 2022-03-03 Novartis Ag Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
IL276901B2 (en) 2018-02-28 2024-03-01 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020184399A1 (fr) * 2019-03-08 2020-09-17 塩野義製薬株式会社 Composition pharmaceutique antibactérienne
US12371441B2 (en) 2019-09-06 2025-07-29 Ariva Med Gmbh Siderophore cephalosporin conjugates and uses thereof
EP4095141A4 (fr) * 2020-01-22 2023-06-28 Shanghai Senhui Medicine Co., Ltd. Composé céphalosporine antibactérien et son application pharmaceutique
TW202220663A (zh) * 2020-07-28 2022-06-01 日商鹽野義製藥股份有限公司 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法
CN116528874A (zh) * 2021-01-12 2023-08-01 上海森辉医药有限公司 一种头孢类抗菌化合物及其制备方法
CN113698365A (zh) * 2021-08-30 2021-11-26 成都大学 一种头孢地尔侧链的制备方法
WO2024245383A1 (fr) * 2023-06-01 2024-12-05 江苏恒瑞医药股份有限公司 Composition pharmaceutique comprenant un composé antibactérien céphalosporine
CN117024377B (zh) * 2023-08-15 2025-04-29 济南大学 一种2-氯-3,4-二对甲氧苯甲氧基-n-(2-(1-吡咯烷)乙基)苯甲酰胺的制备方法
CN117069638A (zh) * 2023-08-17 2023-11-17 济南大学 一种头孢地尔中间体的制备方法
CN117088764B (zh) * 2023-08-24 2026-01-30 济南大学 一种头孢地尔关键中间体的合成和后处理方法
US12225906B1 (en) 2024-09-26 2025-02-18 Terry Earl Brady Pathogenic affinity pathway of infectious or parasitic organisms for nanogram and picogram dosimetry prophylaxis or cure

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS57118588A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel cephalosporin
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
GR79784B (fr) 1983-01-21 1984-10-31 Beecham Group Plc
NO165842C (no) 1984-04-23 1991-04-17 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
EP0168177A3 (fr) 1984-06-28 1987-04-01 Pfizer Limited Céphalosporines antibiotiques
DE3688477T2 (de) 1985-03-01 1993-09-16 Takeda Chemical Industries Ltd Antibakterielle verbindungen, ihre herstellung und verwendung.
JPH068300B2 (ja) * 1985-08-02 1994-02-02 萬有製薬株式会社 新規セフアロスポリン誘導体
EP0211656A3 (fr) 1985-08-10 1988-03-09 Beecham Group Plc Dérivés de céphalosporine, procédé pour leur préparation et les compositions pharmaceutiques les contenant
JPH07107069B2 (ja) * 1985-09-03 1995-11-15 大塚化学株式会社 セフアロスポリン化合物の新規誘導体、その製造法及び該誘導体を含有する医薬組成物
EP0214600B1 (fr) * 1985-09-03 1992-12-02 Otsuka Kagaku Kabushiki Kaisha Dérivés de céphalosporine
JPS62158291A (ja) * 1986-01-07 1987-07-14 Sagami Chem Res Center セフアロスポリン誘導体
US5084453A (en) * 1986-04-14 1992-01-28 Banyu Pharmaceutical Co., Ltd. 1-carboxy-1-vinyloxyimino aminothiazole cephalosporin derivatives
DE3750411T2 (de) * 1986-04-14 1995-03-16 Banyu Pharma Co Ltd Cephalosporinderivate, Verfahren zu ihrer Herstellung und antibakterielle Präparate.
IE61679B1 (en) * 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
GB8719875D0 (en) 1987-08-22 1987-09-30 Beecham Group Plc Compounds
JPH0228185A (ja) 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
GB8811055D0 (en) 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
US5149803A (en) * 1988-05-10 1992-09-22 Imperial Chemical Industries Plc Intermediates for cephalosporin compounds
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
US5244890A (en) * 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
CA2005787A1 (fr) 1988-12-29 1990-06-29 Masao Wada Composes de cephalosporine
JPH02275886A (ja) 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
US5143910A (en) 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5126336A (en) * 1990-08-23 1992-06-30 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5194433A (en) * 1990-11-13 1993-03-16 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
EP0628562A1 (fr) 1993-06-10 1994-12-14 Roussel Uclaf Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments
WO1999033839A1 (fr) 1997-12-26 1999-07-08 Cheil Jedang Corporation Composes derives du cepheme, procede de production associe et composition antibacterienne les contenant
MXPA03008639A (es) 2001-03-27 2005-03-07 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolinas.
JP2003078440A (ja) 2001-08-30 2003-03-14 Kyocera Corp 高周波スイッチ回路
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
WO2003099826A1 (fr) 2002-05-23 2003-12-04 Orchid Chemicals And Pharmaceuticals Limited Nouvelle methode de preparation de cefditorene utilisant le thioester d'acide thiazolylacetique
JP4892926B2 (ja) 2005-10-25 2012-03-07 宇部興産株式会社 スルホン化芳香族ブロック共重合体の製造方法
WO2006104141A1 (fr) 2005-03-29 2006-10-05 Shionogi & Co., Ltd. Dérivé de 3-propénylcéphème
JP4557859B2 (ja) 2005-09-29 2010-10-06 富士通株式会社 周波数分割多重送受信装置及び送受信方法
WO2007096740A2 (fr) 2006-02-20 2007-08-30 Orchid Research Laboratories Limited Nouvelles céphalosporines
WO2007119511A1 (fr) * 2006-03-16 2007-10-25 Astellas Pharma Inc. Composés de céphem et leur utilisation en tant qu'agents antimicrobiens
BRPI0921701B8 (pt) 2008-10-31 2022-11-29 Shionogi & Co Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende
US8883773B2 (en) * 2010-04-05 2014-11-11 Shionogi & Co., Ltd. Cephem compound having pseudo-catechol group
AU2011236933A1 (en) * 2010-04-05 2013-05-02 Shionogi & Co., Ltd. Cephem compound having catechol group
JP5852562B2 (ja) * 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体

Also Published As

Publication number Publication date
BRPI0921701B8 (pt) 2022-11-29
BRPI0921701B1 (pt) 2022-05-03
IL211720A0 (en) 2011-06-30
EP2341053B1 (fr) 2016-01-13
HRP20161408T1 (hr) 2016-12-02
TWI535727B (zh) 2016-06-01
US9238657B2 (en) 2016-01-19
CR20110144A (es) 2011-09-09
HUS2000042I1 (hu) 2020-11-30
EA019520B1 (ru) 2014-04-30
MY155655A (en) 2015-11-13
PE20120010A1 (es) 2012-02-07
JPWO2010050468A1 (ja) 2012-03-29
JP2014065732A (ja) 2014-04-17
LT2960244T (lt) 2016-11-25
CY2020034I1 (el) 2020-11-25
UA105190C2 (ru) 2014-04-25
IL211720A (en) 2015-01-29
PL2960244T3 (pl) 2017-03-31
MX2011004636A (es) 2011-06-20
CA2736953C (fr) 2017-07-11
FIC20200039I1 (fi) 2020-10-19
EP2341053A4 (fr) 2012-08-08
BRPI0921701A2 (pt) 2020-08-11
EP2960244B1 (fr) 2016-09-14
SMT201600397B (it) 2017-01-10
CN102203100A (zh) 2011-09-28
CY1118536T1 (el) 2017-07-12
PT2960244T (pt) 2016-11-02
CY2020034I2 (el) 2021-05-05
KR20110090982A (ko) 2011-08-10
JP5498393B2 (ja) 2014-05-21
LTPA2020530I1 (lt) 2020-11-10
CL2011000939A1 (es) 2011-09-16
DK2960244T3 (en) 2016-11-28
AU2009310959B2 (en) 2015-05-07
EP2960244A1 (fr) 2015-12-30
LTC2960244I2 (lt) 2023-10-10
NL301067I2 (nl) 2020-10-28
EA201170632A1 (ru) 2011-12-30
TW201020259A (en) 2010-06-01
CO6331443A2 (es) 2011-10-20
NL301067I1 (fr) 2020-10-13
FR20C1050I1 (fr) 2020-11-27
WO2010050468A1 (fr) 2010-05-06
NZ591728A (en) 2012-12-21
ME02666B (fr) 2017-06-20
FR20C1050I2 (fr) 2021-10-15
KR101655961B1 (ko) 2016-09-08
ES2564836T3 (es) 2016-03-29
RS55365B1 (sr) 2017-03-31
ZA201102024B (en) 2014-08-27
NO2020035I1 (no) 2020-10-21
AU2009310959A1 (en) 2010-05-06
CA2736953A1 (fr) 2010-05-06
SI2960244T1 (sl) 2017-02-28
US20110190254A1 (en) 2011-08-04
EP2341053A1 (fr) 2011-07-06
ES2602969T3 (es) 2017-02-23
CN102203100B (zh) 2014-08-27
HUE031802T2 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
MA32731B1 (fr) Céphalosporine possédant un groupe catéchol
MA27908A1 (fr) Agents therapeutiques utiles pour le traitement de la douleur
MA33893B1 (fr) Derives de diphenyl-pyrazolopyridines,leur preparation et leur appalication en therapeutique
MA37358B1 (fr) Composition de lutte antiparasitaire comprenant un nouveau dérivé d'iminopyridine
MA27119A1 (fr) Modulateurs tetrahydropyranyle cyclopentyle tetrahydropyrido pyridine de l'activite d'un recepteur de chimiokine
NO20075723L (no) Tiazolforbindelser og fremgangsmater for anvendelse
CA2203618A1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
MA34013B1 (fr) Inhibiteurs du virus de l'hépatite c
MA27831A1 (fr) Procede pour preparer un analogue de la cyclosporine a
MA29323B1 (fr) Composes de l'acide pyridylacetique
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
BG106020A (en) Inhibitors of impdh enzyme
MA30813B1 (fr) Derives de 2-pyridinecarboxamide ayant un effet d'activation sur la gk.
MA28453B1 (fr) Nouveaux insecticides
ATE312100T1 (de) Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
MA32646B1 (fr) Compositions d'antagonistes de pd -1 et methodes d'utilisation associees
WO2005092858A3 (fr) Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
FR2926554B1 (fr) Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
AR044337A1 (es) Procedimiento para potenciar la cognicion usando ziprasidona
WO2005030766A8 (fr) Composes phenyl-carboxamide utiles pour traiter la douleur
FR2426694A1 (fr) Cephalosporines perfectionnees, leur procede de preparation et leur application therapeutique
BRPI0619894B8 (pt) composto de amina e composição farmacêutica